Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuromuscular Channelopathy and Selective NaV1.4 Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SCN4A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Alternative | SCN4A Lentivirus Premade Particles Full-length human SCN4A (NaV1.4) for stable cell line construction. Preserves native 24-transmembrane conformation. |
View SCN4A Products |
| Gene Delivery | SCN4A Promise-ORF / Lentivirus Sequence-verified expression clones optimized for high-titer mammalian transduction. |
View SCN4A Products |
| Benchmark Ab | Anti-SCN4A Recombinant Antibody Sequence-derived positive control for surface expression validation and IHC/Flow Cytometry. |
View SCN4A Products |
| Validator | SCN4A siRNA Set Target-specific knockdown pool for functional assay validation and specificity controls. |
View SCN4A Products |
| Related Target A | SCN5A (NaV1.5) Essential counter-screening target to eliminate cardiotoxicity and QT-prolongation risks. |
View SCN5A Products |
| Related Target B | SCN9A (NaV1.7) Comparative target for peripheral nerve selectivity profiling in pain and neuromuscular programs. |
View SCN9A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 24-TM Protein | Lentivirus-mediated stable cell line expression avoids structural distortion, enabling robust patch-clamp and FLIPR assays. |
| Cardiac Safety Counter-Screening | High-titer SCN5A (NaV1.5) expression systems available for parallel selectivity profiling. |
| Lack of Reliable Positive Controls | Recombinant sequence-verified benchmark antibodies ensure assay reproducibility. |
| Off-Target Phenotypes | Sequence-verified siRNA sets provide precise target knockdown to validate primary screening hits. |
Live SCN4A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SCN4A (NaV1.4), the primary voltage-gated sodium channel in skeletal muscle, is undergoing a major paradigm shift. Historically focused on symptomatic management of skeletal muscle channelopathies (such as Myotonia Congenita, Hyperkalemic Periodic Paralysis, and Paramyotonia Congenita) using non-selective sodium channel blockers like mexiletine, the industry is now pivoting toward highly selective small-molecule modulators and gene therapies.
As the structural biology of voltage-gated sodium channels reaches near-atomic resolution via Cryo-EM, the next wave of drug discovery is focused on achieving absolute subtype selectivity. Avoiding off-target inhibition of cardiac NaV1.5 (SCN5A) and central nervous system NaV channels (such as NaV1.1/SCN1A) is the primary hurdle for next-generation SCN4A therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Highly Selective Small Molecules | Vertex Pharmaceuticals, Roche | Myotonia Congenita, Periodic Paralysis | Electrophysiology & FLIPR screening (Requires SCN4A Stable Cell Lines via Lentivirus) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | Gain-of-Function SCN4A Channelopathies | Target Knockdown Validation (Requires SCN4A siRNA & qPCR controls) |
| Gene Therapy / CRISPR | Academic Spin-outs | Severe Congenital Myasthenic Syndromes | In Vitro Expression Verification (Requires Sequence-Verified SCN4A ORF) |